• Inari Medical Reports Fourth Quarter 2023 Financial Results

    Source: Nasdaq GlobeNewswire / 28 Feb 2024 16:05:01   America/New_York

    IRVINE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its fourth quarter and full year ended December 31, 2023.

    Fourth Quarter Financial and Recent Business Highlights

    • Generated revenue of $132.1 million in Q4 of 2023, up 22.6% over the same quarter last year.
    • GAAP operating loss was $9.3 million in Q4 of 2023, compared to a $5.9 million operating loss in the same quarter of last year.
    • Non-GAAP operating loss was $0.3 million in Q4 of 2023, compared to a $5.9 million non-GAAP operating loss in the same quarter of last year.
    • Closed LimFlow acquisition on November 15, 2023.
    • Completed enrollment in the PEERLESS randomized controlled trial.

    “Our solid fourth quarter performance was driven by strong underlying procedural growth and crisp execution across our three growth pillars led by our core VTE business, with meaningful contributions from emerging therapies and international geographies,” said Drew Hykes, CEO of Inari Medical. "We also closed on the acquisition of LimFlow in mid-November. In terms of clinical evidence generation, the completion of enrollment in PEERLESS, our first RCT, represents an important step forward in our commitment to generating the highest level of clinical evidence. Taken together, these efforts will result in the establishment of our therapy as the standard of care for VTE. With a strong VTE foundation and encouraging commercial traction across emerging therapies and international, we remain confident in our ability to generate sustainable growth for many years to come. Most importantly, we remain fully committed to advancing our mission of addressing major unmet needs for patients."

    Fourth Quarter 2023 Financial Results
    Revenue was $132.1 million for the fourth quarter of 2023, up 22.6% compared to $107.8 million for the fourth quarter of 2022. The increase over the prior year quarter was driven primarily by increased adoption of our procedures, new products, and global commercial expansion.

    Gross profit was $115.1 million for the fourth quarter of 2023, compared to $94.6 million for the fourth quarter of 2022. Gross margin was 87.1% for the fourth quarter of 2023, compared to 87.8% for the fourth quarter of 2022.

    Operating expenses for the fourth quarter of 2023 were $124.4 million, compared to $100.5 million for the fourth quarter of 2022. The increase was mainly driven by transaction costs associated with the acquisition of LimFlow; personnel-related expenses, including commissions and stock-based compensation associated with increased headcount to fund the expansion of the commercial, research and development, clinical, and support organizations; sales and marketing related efforts; and amortization expense related to an intangible asset acquired in the LimFlow acquisition.

    GAAP operating loss was $9.3 million in the fourth quarter of 2023, compared with a $5.9 million GAAP operating loss for the fourth quarter of 2022.

    Non-GAAP operating loss was $0.3 million in the fourth quarter of 2023. The following items were excluded from the non-GAAP operating loss: acquisition-related costs of $7.7 million and acquired intangible asset amortization of $1.3 million. There were no non-GAAP adjustments related to the company’s operating loss for the fourth quarter of 2022.

    Net loss was $4.7 million for the fourth quarter of 2023 and net loss per share was $0.08 on a weighted-average basic and diluted share count of 57.6 million, compared to a net loss of $5.8 million and a net loss per share of $0.11 on a weighted-average basic and diluted share count of 53.6 million, in the same period of the prior year.

    Full Year 2023 Financial Results
    Revenue was $493.6 million for the year ended December 31, 2023, up 28.7% compared to $383.5 million in the prior year. The increase over the prior period was driven primarily by continued U.S. and international commercial expansion, increased adoption of our procedures, and introduction of new products.

    Gross profit was $434.6 million for the full year of 2023, compared to $339.0 million for the prior year. Gross margin was 88.0% for the full year of 2023, compared to 88.4% for the prior year.

    Operating expenses for the full year of 2023 were $448.6 million, compared to $367.1 million for the prior year. The increase was mainly driven by personnel-related expenses, including commissions and stock-based compensation associated with increased headcount to fund the expansion of the commercial, research and development, clinical, and support organizations.

    GAAP operating loss was $14.0 million for the full year of 2023, compared with a $28.1 million GAAP operating loss in the prior year.

    Non-GAAP operating loss was $2.4 million for the full year of 2023. The following items were excluded from the non-GAAP operating loss: acquisition-related costs of $10.4 million and acquired intangible asset amortization of $1.3 million. There were no non-GAAP adjustments related to the company’s full year 2022 operating loss.

    Net loss was $1.6 million for the full year of 2023 and net loss per share was $0.03 on a weighted-average basic and diluted share count of 56.8 million, compared to a net loss of $29.3 million and net loss per share of $0.55 on a weighted-average basic and diluted share count of 52.8 million.

    Full Year 2024 Revenue Guidance

    • Inari expects full year 2024 revenue of $580 million to $595 million, reflecting growth of approximately 17.5% to 20.5% over 2023.
    • The company still expects to reach sustained operating profitability in the first half of 2025.

    Webcast and Conference Call Information
    Inari Medical will host a conference call to discuss the fourth quarter and full year 2023 financial results and acquisition of LimFlow after market close on February 28, 2024 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. The conference call can be accessed live by dialing (844) 825-9789 for domestic callers or (412) 317-5180 for international callers. The live webinar and presentation may be accessed by visiting the Events Section of the Inari investor relations website at ir.inarimedical.com.

    Use of Non-GAAP Financial Measures
    This press release contains references to non-GAAP operating income (loss), which is considered a non-GAAP financial measure. This means that non-GAAP operating income (loss) is determined by methods other than in accordance with accounting principles generally accepted in the United States (GAAP). As used by Inari, non-GAAP operating income (loss) excludes from GAAP operating income (loss) the following items: amortization of acquired intangible assets and acquisition-related costs. Beginning in the fourth quarter of 2023, we began presenting non-GAAP operating income (loss) to exclude these charges because we believe these charges are significantly impacted by the timing and valuation of acquisitions, such as our LimFlow acquisition in the fourth quarter of 2023. Our management believes the presentation of non-GAAP operating income (loss) is useful because it provides meaningful comparisons to prior periods and provides visibility to our underlying operating performance and an additional means to evaluate the cost and expense trends excluding the impact of these acquisition-related items, which are not related to our core business operations.

    Our definition of non-GAAP operating income (loss) may differ from similarly titled measures used by others. Non-GAAP operating income (loss) should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. We encourage investors to review the reconciliation of non-GAAP operating income (loss) to GAAP operating income (loss), which has been provided in the financial statement tables included in this press release.

    About Inari Medical, Inc.
    Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underserved health needs. In addition to our purpose-built solutions, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous disease, including venous thromboembolism, chronic venous disease, and beyond. We are just getting started.

    Forward Looking Statements
    Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements include expectations regarding Inari’s core business, its ability to integrate LimFlow, expectations regarding future growth, Inari's ability to meet customers' needs, and timing for achieving sustained operating profitability, and are based on Inari’s current expectations, forecasts, and assumptions. Forward-looking statements are subject to inherent uncertainties, risks and assumptions that are difficult to predict, and actual outcomes and results could differ materially due to a number of factors. These and other risks and uncertainties include those described more fully in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the period ended December 31, 2023, and in Inari’s other reports filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this announcement are based on information available to Inari as of the date hereof and are made only as of the date of this release. Inari undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing Inari’s views as of any date subsequent to the date of this press release. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Inari.

    Investor Contact:
    John Hsu, CFA
    VP, Investor Relations
    949-658-3889
    IR@inarimedical.com

    INARI MEDICAL, INC.
    Consolidated Statements of Operations and Comprehensive Income (Loss)
    (in thousands, except share and per share data)
     
     Three Months Ended
    December 31,
     Years ended December 31,
     2023 2022 2023 2022
    Revenue$132,094  $107,771  $493,632  $383,471 
    Cost of goods sold 17,006   13,128   59,068   44,506 
    Gross profit 115,088   94,643   434,564   338,965 
    Operating expenses       
    Research and development 22,892   20,412   87,533   74,221 
    Selling, general and administrative 101,495   80,122   361,063   292,843 
    Total operating expenses 124,387   100,534   448,596   367,064 
    Loss from operations (9,299)  (5,891)  (14,032)  (28,099)
    Other income (expense)       
    Interest income 2,714   970   15,613   1,852 
    Interest expense (69)  (74)  (196)  (294)
    Other income 3,478   187   2,861   356 
    Total other income 6,123   1,083   18,278   1,914 
    (Loss) income before income taxes (3,176)  (4,808)  4,246   (26,185)
    Provision for income taxes 1,491   990   5,882   3,082 
    Net loss$(4,667) $(5,798) $(1,636) $(29,267)
    Other comprehensive income (loss)       
    Foreign currency translation adjustments 10,002   222   9,864   (592)
    Unrealized gain (loss) on available-for-sale debt securities 41   1,572   (1,828)  1,843 
    Total other comprehensive income 10,043   1,794   8,036   1,251 
    Comprehensive income (loss)$5,376  $(4,004) $6,400  $(28,016)
    Net loss per share       
    Basic$(0.08) $(0.11) $(0.03) $(0.55)
    Diluted$(0.08) $(0.11) $(0.03) $(0.55)
    Weighted average common shares used to compute net loss per share       
    Basic 57,639,591   53,610,347   56,770,657   52,837,674 
    Diluted 57,639,591   53,610,347   56,770,657   52,837,674 
                    


    INARI MEDICAL, INC.
    Consolidated Balance Sheets
    (in thousands, except share data)
        
     December 31,
    2023
     December 31,
    2022
    Assets   
    Current assets   
    Cash and cash equivalents$38,597  $60,222 
    Restricted cash 611    
    Short-term investments in debt securities 76,855   266,179 
    Accounts receivable, net 70,119   58,611 
    Inventories, net 42,900   32,581 
    Prepaid expenses and other current assets 6,481   5,312 
    Total current assets 235,563   422,905 
    Property and equipment, net 20,929   21,655 
    Operating lease right-of-use assets 48,407   50,703 
    Goodwill 214,335    
    Intangible assets 150,884    
    Deposits and other assets 4,117   8,889 
    Total assets$674,235  $504,152 
    Liabilities and Stockholders' Equity   
    Current liabilities   
    Accounts payable$10,577  $7,659 
    Payroll-related accruals 48,706   38,955 
    Accrued expenses and other current liabilities 15,364   8,249 
    Operating lease liabilities, current portion 1,692   1,311 
    Total current liabilities 76,339   56,174 
    Operating lease liabilities, noncurrent portion 30,355   30,976 
    Deferred tax liability 36,231    
    Other long-term liability 66,400    
    Total liabilities 209,325   87,150 
    Commitments and contingencies   
    Stockholders' equity   
    Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2023 and 2022     
    Common stock, $0.001 par value, 300,000,000 shares authorized as of December 31, 2023 and 2022; 57,762,414 and 54,021,656 shares issued and outstanding as of December 31, 2023 and 2022, respectively 58   54 
    Additional paid in capital 504,453   462,949 
    Accumulated other comprehensive income 8,885   849 
    Accumulated deficit (48,486)  (46,850)
    Total stockholders' equity 464,910   417,002 
    Total liabilities and stockholders' equity$674,235  $504,152 
            


    INARI MEDICAL, INC.
    Reconciliation of GAAP Operating Loss to Non-GAAP Operating Loss
    (in thousands)
    (Unaudited)
        
     Three Months Ended
    December 31,
     Years ended December 31,
     2023 2022 2023 2022
    GAAP Operating loss$(9,299) $(5,891) $(14,032) $(28,099)
    Non-GAAP Adjustments:       
    Amortization of acquired intangible assets 1,255      1,255    
    Acquisition-related expense (a) 7,725      10,406    
    Non-GAAP Operating loss$(319) $(5,891) $(2,371) $(28,099)
                    

    ________________

    (a) For three months ended December 31, 2023, acquisition related expenses included $6.0 million of transaction costs and $1.7 million of severance and integration related expenses. For the year ended December 31, 2023, acquisition related expenses included $8.7 million of transaction costs and $1.7 million of severance and integration related expenses.

    Revenue Disaggregation

    Commencing in the fourth quarter of 2023, we began presenting revenue bifurcated between VTE and Emerging Therapies. The following table presents the amount of revenue in VTE and Emerging Therapies recognized for the periods presented (in thousands, unaudited):

     Three Months
    Ended 
    December 31,
     Three Months
    Ended 
    September 30,
     Three Months
    Ended 
    June 30,
     Three Months
    Ended 
    March 31,
     2023 2023 2023 2023
    VTE$126,671 $121,460 $114,086 $114,058
    Emerging Therapies 5,423  4,906  4,919  2,109
    Total Revenue$132,094 $126,366 $119,005 $116,167
                


     Three Months
    Ended
    December 31,
     Three Months
    Ended
    September 30,
     Three Months
    Ended
    June 30,
     Three Months
    Ended
    March 31,
     2022 2022 2022 2022
    VTE$105,978 $95,980 $92,721 $86,752
    Emerging Therapies 1,793  224  23  
    Total Revenue$107,771 $96,204 $92,744 $86,752


    Primary Logo

Share on,